Vertex Pharmaceuticals said Monday that the Food and Drug Administration had suspended an early-stage clinical trial of its stem-cell therapy for type 1 diabetes, citing “insufficient information” to support an increase in dosing.
The FDA’s decision to place a clinical hold on the diabetes therapy, called VX-880, was a “surprise,” Vertex Chief Operating Officer Stuart Arbuckle told STAT. The company and the study’s independent monitors recently reviewed data from the VX-880 study, concluding that there were no safety or efficacy issues to preclude advancing from a half dose to a full dose of the therapy.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED"type" - Google News
May 02, 2022 at 09:28PM
https://ift.tt/z8XOk01
FDA suspends early study of Vertex stem-cell therapy for type 1 diabetes - STAT
"type" - Google News
https://ift.tt/q7LgN0S
https://ift.tt/31U0DVW
Bagikan Berita Ini
Related Posts :
Intelligent Transportation System Market Size, Share & Trends By Type, By Application, By Region And Segment Forecasts, 2020 - 2027 - GlobeNewswire- Certain blood types trigger more severe COVID-19 symptoms, study finds - KVUE.com
- More studies show potential for slowing type 1 diabetes progression - medwireNews
- COVID-19 Impact on NPK Fertilizers Market by Nutrient Type, Crop Type, and Region - Global Forecast to 2021 - GlobeNewswire
- Alice Spawls · At the Type Archive · LRB 2 July 2020 - London Review of Books
0 Response to "FDA suspends early study of Vertex stem-cell therapy for type 1 diabetes - STAT"
Post a Comment